Clinical trials: Geriatric Disorders
Overactive Bladder
A Study Of Efficacy And Safety Of Fesoterodine In Vulnerable Elderly Subjects With Overactive Bladder
This study is designed to assess the efficacy and safety of a flexible dose regimen of fesoterodine on urgency urinary incontinence (UUI) episodes in vulnerable elderly subjects with overactive bladder (OAB).
- Trial name
- NCT00928070
- Testing
- Fesoterodine
- Where
- 125 sites in United States
- Volunteers
- 566 people
- Sponsor
- Pfizer
Treatment Resistant Depressive Disorder
Ketamine for Treatment Resistant Late-Life Depression
The purpose of this study is to examine the effectiveness of a single infusion of ketamine (KET), to determine which dose is optimal 7 days after infusion using Bayesian Adaptive Randomization, and to learn about how ketamine…
- Trial name
- NCT02556606
- Testing
- Ketamine, Midazolam
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- VA Office of Research and Development
Impaired Renal Function
Study of SSP-004184 (FBS0701) in Healthy Adults and Elderly Subjects and in Subjects With Impaired Renal Function
Shire is developing SSP-004184 (FBS0701), a novel iron chelator , for the treatment of chronic iron overload in patients with transfusion-dependent hereditary and acquired anemias.
- Trial name
- NCT01716455
- Testing
- SSP-004184
- Where
- 2 sites in United States
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Shire
Major Depression
Increasing Use of Mental Health Services
The purpose of this study is to test the effectiveness of Open Door (previously known as the Treatment Initiation Program [TIP]), a brief psychosocial intervention to address the psychological barriers to care and improve the use…
- Trial name
- OpenDoor (NCT00605358)
- Testing
- Open Door intervention
- Where
- United States
- Volunteers
- 161 people
- Sponsor
- Weill Medical College of Cornell University
Weakness, Muscle, Delirium in Old Age
YOOMI: Effect of Gamified Physical Therapy Exercise Software on Inpatient Mobility
Patients admitted to the hospital often develop functional impairments due to being in bed most of the day. Each day of bedrest leads to significant muscle loss.
- Conditions
- Weakness, Muscle, Delirium in Old Age, Muscle Atrophy or Weakness, Muscle Loss
- Trial name
- YOOMI (NCT05815017)
- Testing
- Yoomi Physical Therapy Software
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Rutgers, The State University of New Jersey
Coronary Artery Disease
Comparison of Prasugrel and Clopidogrel in Very Elderly and Non-Elderly Patients With Stable Coronary Artery Disease
The 5-milligram (mg) maintenance dose (MD) of prasugrel in very elderly patients with coronary artery disease produces a pharmacodynamic response within the same therapeutic range as 10-mg MD in non-elderly patients.
- Trial name
- GENERATIONS (NCT01107912)
- Testing
- prasugrel, clopidogrel
- Where
- 7 sites in United States, Ireland and 2 more
- Volunteers
- 155 people
- Sponsor
- Eli Lilly and Company
Cough
A Study of Camlipixant in Male and Female Healthy Participants and Participants With Hepatic Impairment Aged 18-75 Years of Age
The purpose of this study is to assess the effect of Hepatic impairment (HI) on the Pharmacokinetic (PK) profile and safety of Camlipixant.
- Trial name
- NCT06222892
- Testing
- Camlipixant
- Where
- 3 sites in United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Bellus Health Inc. - a GSK company
Perennial Allergic Rhinitis
Long Term Safety and Efficacy of Fixed Dose Combination GSP 301 Nasal Spray (NS) in the Treatment of Perennial Allergic Rhinitis (PAR)
To evaluate the long term safety and efficacy of GSP 301 NS compared to 2 placebo NS formulations for the treatment of perennial allergic rhinitis (subjects 12 years of age and older)
- Trial name
- GSP 301-303 (NCT02709538)
- Testing
- GSP 301 NS
- Where
- 34 sites in United States
- Volunteers
- 601 people
- Sponsor
- Glenmark Specialty S.A.
Orthomyxoviridae Infection, Influenza
Immunogenicity of High-dose Inactivated, Split-virion Influenza Vaccine Versus Standard Fluzone Vaccine in the Elderly
Compared to young adults, the elderly mount a lower antibody response to vaccination. Thus, improvement of the immune response to influenza vaccination in this age group, which is at higher risk for influenza-related morbidity…
- Conditions
- Orthomyxoviridae Infection, Influenza, Myxovirus Infection
- Trial name
- NCT00391053
- Testing
- High-Dose Inactivated, Split-Virion Influenza Vaccine, Inactivated, Split-Virion Influenza Vaccine
- Where
- 28 sites in United States
- Volunteers
- 3,851 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Developmental Language Disorder and Language Impairment, Specific Language Impairment
Retrieval-Based Word Learning in Developmental Language Disorder During Book Reading II
Children with developmental language disorder (DLD; also referred to as specific language impairment) experience a significant deficit in language ability that is longstanding and harmful to the children's academic, social, and…
- Conditions
- Developmental Language Disorder and Language Impairment, Specific Language Impairment, Language Development
- Trial name
- NCT07048392
- Testing
- Retrieval-based word learning: Repeated Spaced Retrieval condition, Retrieval-based word learning: Repeated Study condition
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Purdue University
Hypercholesterolemia
Ezetimibe and Atorvastatin vs. Atorvastatin in Patients Age 65 and Older at High Risk for Coronary Heart Disease (CHD)(0653-112)
A 12 week clinical trial in patients 65 years of age and older with hypercholesterolemia at high risk for coronary heart disease to study the effects of atorvastatin and ezetimibe given in combination and two higher doses of…
- Trial name
- NCT00418834
- Testing
- ezetimibe and atorvastatin, atorvastatin
- Volunteers
- 1,053 people
- Sponsor
- Organon and Co
Inflammation, Insulin Sensitivity
Exercise and Inflammation in the Elderly
Persistent low-grade inflammation and impaired fibrinolysis, are independent predictors of several chronic diseases highly prevalent in the older Veteran population including cardiovascular disease (CVD), stroke, and diabetes.
- Trial name
- IRIS (NCT00753363)
- Testing
- Weight Loss, Aerobic Exercise Training
- Where
- United States
- Volunteers
- 119 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
Influenza
Immunogenicity & Safety of GSK's Avian Flu Vaccine 1557484A Given to Adults Aged 18-64 Years
The purpose of this observer-blind study is to determine whether GSK's avian flu vaccine GSK 1557484A is immunogenic when given to adults aged 18-64 years.
- Trial name
- NCT00771615
- Testing
- GSK A/turkey H5N1 Influenza vaccine
- Where
- 10 sites in United States, Canada
- Volunteers
- 469 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Hypertension
Efficacy and Safety of Aliskiren 75 mg, 150 mg, and 300 mg in Elderly Patients With Essential Hypertension When Given With a Light Meal in a 8 Week Placebo-controlled Study
This study will evaluate the efficacy and safety of aliskiren 75 mg, 150 mg, and 300 mg in elderly patients with essential hypertension when given with a light meal.
- Trial name
- NCT00706134
- Testing
- Aliskiren 75 mg, Aliskiren 150 mg, Aliskiren 300 mg
- Where
- 8 sites in Argentina, Czechia and 6 more
- Volunteers
- 756 people
- Sponsor
- Novartis
Seasonal Influenza Vaccine
Safety and Immunogenicity of Trivalent Subunit Influenza Vaccine Produced in Mammalian Cell Culture Using the Strain Composition 2007/2008
Annual trial for registration of sub-unit influenza vaccine produced in mammalian cell culture, using the strain composition 2007/2008, when administered to adult and elderly subjects
- Trial name
- NCT00511914
- Testing
- cTIV
- Where
- 2 sites in Germany
- Volunteers
- 135 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Influenza
Safety and Immunogenicity of Two Doses of a Tetravalent Influenza Vaccine in Adults Aged 18 Years and Above
Evaluate the immune response and reactogenicity of H5N1 vaccination in adults aged 18 years and above (as part of a tetravalent vaccine)
- Trial name
- NCT00620815
- Testing
- Pandemic influenza vaccine + seasonal influenza vaccine /pandemic influenza vaccine, Pandemic influenza vaccine + seasonal influenza vaccine / pandemic influenza vaccine
- Where
- 2 sites in Germany
- Volunteers
- 601 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Acute Myeloid Leukemia
Efficacy Study of Anti-KIR Monoclonal Antibody as Maintenance Treatment in Acute Myeloid Leukemia (EFFIKIR)
Double-Blind Placebo-Controlled Randomized Phase 2 Study evaluating the efficacy of lirilumab (IPH2102/BMS-986015) as Maintenance Treatment administered in elderly patients with Acute Myeloid Leukemia (AML) in first complete…
- Trial name
- EFFIKIR (NCT01687387)
- Testing
- IPH2102 at 0.1 mg/kg, IPH2102 at 1 mg/kg
- Where
- 43 sites in France
- Volunteers
- 152 people
- Sponsor
- Innate Pharma
Influenza
Evaluation of Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2186877A in Adults 65 Years and Older
The purpose of this study is to evaluate the safety and immunogenicity of GlaxoSmithKline Biologicals' influenza vaccine GSK2186877A in adults 65 year of age and older.
- Trial name
- NCT00760617
- Testing
- GSK Bio's influenza vaccine GSK2186877A, Fluarix
- Where
- 25 sites in Germany, Netherlands and 1 more
- Volunteers
- 526 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US
This randomized, modified double-blind, active-controlled, multi-center trial assessed the safety and immunogenicity of the high-dose quadrivalent influenza vaccine (QIV-HD) compared to either the licensed or investigational…
- Trial name
- NCT03282240
- Testing
- QIV-HD, Licensed TIV-HD1, Investigational TIV-HD2
- Where
- 36 sites in United States
- Volunteers
- 2,670 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Hypertension, Pulmonary
Efficacy and Safety of Ambrisentan in Children 8-18yrs
A 6-month (24-week), randomized, open label evaluation of the safety, tolerability, and efficacy of a high and low dose ambrisentan (adjusted for body weight) treatment group in subjects aged 8 years up to 18 years with pulmonary…
- Trial name
- NCT01332331
- Testing
- Ambrisentan - low dose, Ambrisentan - high dose
- Where
- 24 sites in United States, Argentina and 7 more
- Volunteers
- 41 people
- Sponsor
- GlaxoSmithKline
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.